Radiopharmaceuticals for thrombus detection

Selection, preparation, and critical evaluation

Kenneth Krohn, Linda C. Knight

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Nearly a decade has passed since the introduction of 125I-fibrinogen as a tracer to aid in the clinical diagnosis of thrombosis. During this time many new radiopharmaceuticals have been developed for the detection of thrombi. Most of these have been designed to overcome the primary disadvantages of 125I-fibrinogen for uptake tests, namely, that it is limited to evaluation of the extremities, and it does not provide a scintigraphic image. Iodine-125-fibrinogen is now commercially available in the United States. We, therefore, concentrated our review on agents labeled with short-lived gamma-emitting nuclides useful for scintigraphy: 123I, 111In, 77Br, and 99mTc. In addition to being tagged with a variety of short-lived isotopes, fibrinogen has been chemically modified by overiodination and by clot formation/dissolution in attempts to accelerate its biologic clearance. These modifications have resulted in higher thrombus: blood ratios measured at earlier times when the photon flux is still high. Labeled leukocytes and platelets also have been tested as thrombus-localizing agents, and several components of the fibrinolytic system, including plasminogen, streptokinase, and urokinase, have been purified and labeled with iodine and/or technetium. The later agents could prove particularly useful for localizing older thrombi in which net fibrin deposition has slowed. Among the radiopharmaceuticals described for thrombus scintigraphy, chemically modified and fast clearing 123I-fibrinogen, 111In-platelets, and 123I-plasminogen show the greatest potential and should find extensive clinical application in the immediate future.

Original languageEnglish (US)
Pages (from-to)219-228
Number of pages10
JournalSeminars in Nuclear Medicine
Volume7
Issue number3
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Thrombosis
Fibrinogen
Plasminogen
Radionuclide Imaging
Iodine
Blood Platelets
Streptokinase
Technetium
Urokinase-Type Plasminogen Activator
Fibrin
Photons
Isotopes
Leukocytes
Extremities

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Radiopharmaceuticals for thrombus detection : Selection, preparation, and critical evaluation. / Krohn, Kenneth; Knight, Linda C.

In: Seminars in Nuclear Medicine, Vol. 7, No. 3, 1977, p. 219-228.

Research output: Contribution to journalArticle

@article{0066c525b17148838d6e2ec966ce1591,
title = "Radiopharmaceuticals for thrombus detection: Selection, preparation, and critical evaluation",
abstract = "Nearly a decade has passed since the introduction of 125I-fibrinogen as a tracer to aid in the clinical diagnosis of thrombosis. During this time many new radiopharmaceuticals have been developed for the detection of thrombi. Most of these have been designed to overcome the primary disadvantages of 125I-fibrinogen for uptake tests, namely, that it is limited to evaluation of the extremities, and it does not provide a scintigraphic image. Iodine-125-fibrinogen is now commercially available in the United States. We, therefore, concentrated our review on agents labeled with short-lived gamma-emitting nuclides useful for scintigraphy: 123I, 111In, 77Br, and 99mTc. In addition to being tagged with a variety of short-lived isotopes, fibrinogen has been chemically modified by overiodination and by clot formation/dissolution in attempts to accelerate its biologic clearance. These modifications have resulted in higher thrombus: blood ratios measured at earlier times when the photon flux is still high. Labeled leukocytes and platelets also have been tested as thrombus-localizing agents, and several components of the fibrinolytic system, including plasminogen, streptokinase, and urokinase, have been purified and labeled with iodine and/or technetium. The later agents could prove particularly useful for localizing older thrombi in which net fibrin deposition has slowed. Among the radiopharmaceuticals described for thrombus scintigraphy, chemically modified and fast clearing 123I-fibrinogen, 111In-platelets, and 123I-plasminogen show the greatest potential and should find extensive clinical application in the immediate future.",
author = "Kenneth Krohn and Knight, {Linda C.}",
year = "1977",
doi = "10.1016/S0001-2998(77)80023-8",
language = "English (US)",
volume = "7",
pages = "219--228",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Radiopharmaceuticals for thrombus detection

T2 - Selection, preparation, and critical evaluation

AU - Krohn, Kenneth

AU - Knight, Linda C.

PY - 1977

Y1 - 1977

N2 - Nearly a decade has passed since the introduction of 125I-fibrinogen as a tracer to aid in the clinical diagnosis of thrombosis. During this time many new radiopharmaceuticals have been developed for the detection of thrombi. Most of these have been designed to overcome the primary disadvantages of 125I-fibrinogen for uptake tests, namely, that it is limited to evaluation of the extremities, and it does not provide a scintigraphic image. Iodine-125-fibrinogen is now commercially available in the United States. We, therefore, concentrated our review on agents labeled with short-lived gamma-emitting nuclides useful for scintigraphy: 123I, 111In, 77Br, and 99mTc. In addition to being tagged with a variety of short-lived isotopes, fibrinogen has been chemically modified by overiodination and by clot formation/dissolution in attempts to accelerate its biologic clearance. These modifications have resulted in higher thrombus: blood ratios measured at earlier times when the photon flux is still high. Labeled leukocytes and platelets also have been tested as thrombus-localizing agents, and several components of the fibrinolytic system, including plasminogen, streptokinase, and urokinase, have been purified and labeled with iodine and/or technetium. The later agents could prove particularly useful for localizing older thrombi in which net fibrin deposition has slowed. Among the radiopharmaceuticals described for thrombus scintigraphy, chemically modified and fast clearing 123I-fibrinogen, 111In-platelets, and 123I-plasminogen show the greatest potential and should find extensive clinical application in the immediate future.

AB - Nearly a decade has passed since the introduction of 125I-fibrinogen as a tracer to aid in the clinical diagnosis of thrombosis. During this time many new radiopharmaceuticals have been developed for the detection of thrombi. Most of these have been designed to overcome the primary disadvantages of 125I-fibrinogen for uptake tests, namely, that it is limited to evaluation of the extremities, and it does not provide a scintigraphic image. Iodine-125-fibrinogen is now commercially available in the United States. We, therefore, concentrated our review on agents labeled with short-lived gamma-emitting nuclides useful for scintigraphy: 123I, 111In, 77Br, and 99mTc. In addition to being tagged with a variety of short-lived isotopes, fibrinogen has been chemically modified by overiodination and by clot formation/dissolution in attempts to accelerate its biologic clearance. These modifications have resulted in higher thrombus: blood ratios measured at earlier times when the photon flux is still high. Labeled leukocytes and platelets also have been tested as thrombus-localizing agents, and several components of the fibrinolytic system, including plasminogen, streptokinase, and urokinase, have been purified and labeled with iodine and/or technetium. The later agents could prove particularly useful for localizing older thrombi in which net fibrin deposition has slowed. Among the radiopharmaceuticals described for thrombus scintigraphy, chemically modified and fast clearing 123I-fibrinogen, 111In-platelets, and 123I-plasminogen show the greatest potential and should find extensive clinical application in the immediate future.

UR - http://www.scopus.com/inward/record.url?scp=0017744787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017744787&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(77)80023-8

DO - 10.1016/S0001-2998(77)80023-8

M3 - Article

VL - 7

SP - 219

EP - 228

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -